The M&A Pool Set to Accelerate Biotech Innovation

Pathfinders in Biopharma - A podcast by RBC Capital Markets

Categories:

Business

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.